StopUMTS Logo
how to get rid of moles 
Zoeken
   
Voorlichting
20/06/18Antennebureau: Resultaten
12/06/18Geluid van diverse RF str
Artikelen
15/06/18The 25% Revolution—How
07/06/18Bees, Birds and mankind D
07/06/18Is your high blood sugar
04/06/18Verstouwbare waterafstote
31/05/18Fatal collision? Are wire
29/05/18Researcher Explains How E
Berichten Nederland
21/06/18Leeuwarden: straling 5G n
18/06/18‘Nederland wordt digita
15/06/18Duurzaam Antennebeleid We
15/06/1816 juni: Internationale E
09/06/18Buurt in Kerkdriel wil ze
Berichten België
16/06/18Scherpenheuvel-Zichem: Be
14/06/18Tommelein laat straling d
Berichten Internationaal
19/06/18Oostenrijk: Wordt uitzend
07/06/18Oostenrijk: Ärztekammer
04/06/18The roll out of 5G wirele
03/06/18Top mobile phone firms wa
Ervaringen | Appellen/oproepen
28/05/18Stralingsarme werkplek
28/05/18Ervaring in Denemarken
23/05/18Energieverbruik 2 keer zo
Onderzoeken
21/06/18Absorption of wireless ra
17/06/18Metabolic and Genetic Scr
12/06/18The human skin as a sub-T
Veel gestelde vragen
13/05/17Vakantie? Witte zo
10/07/16Zeven veel gestelde vrage
Juridische informatie
01/06/18Wetgeving hoogspanningsli
15/05/18Brit dad sues Nokia for u
02/03/18Formal Complaint to the E
Oproepen
15/06/18Stem voor plan voor een w
24/05/18Lezing in Westerhoven: Sm
25/04/18Workshop: EHS en omgaan m
Folders
10/09/17Brochures, folders, websi
29/04/16USA: Meer dan 50 tips voo
Briefwisselingen | Archief: 2008, 2005
28/05/18Elektromagnetische velden
23/05/18Mail naar Brandpunt over
Illustraties
 Algemeen
 Fotoalbum zendmasten
 Wetenschappelijke illustraties
USA/Brazilië: Behandeling leverkanker met zeer zwakke elektromagnetische velden.    
Ga naar overzicht berichten in: Onderzoeken

USA/Brazilië: Behandeling leverkanker met zeer zwakke elektromagnetische velden.
dinsdag, 16 augustus 2011 - Dossier: Algemeen


Gerelateerd artikel: Berichten%20Internationaal/5991

Bron: British Journal of Cancer 9 August 2011; doi: 10.1038/bjc.2011.292

Treatment of advanced hepatocellular carcinoma with very low levels of amplitude-modulated electromagnetic fields

F P Costa 1, A C de Oliveira 1, R Meirelles 1, M C C Machado 1, T Zanesco 1, R Surjan 1,
M C Chammas 2, M de Souza Rocha 2,
D Morgan 3,
A Cantor 4,
J Zimmerman 5,
I Brezovich 6,
N Kuster 7,
A Barbault 8 and
B Pasche 5

1.
Department of Transplantation and Liver Surgery, Hospital das Clínicas da Faculdade de Medicina, University of São Paulo, Av. Dr. Enéas de Carvalho Aguiar, 255, São Paulo 05403-000, Brazil

2.
Department of Radiology, Hospital das Clínicas, University of São Paulo, São Paulo 05403-000, Brazil

3.
Department of Radiology, University of Alabama at Birmingham and UAB Comprehensive Cancer Center, Birmingham, AL 35294, USA

4.
Biostatistics and Bioinformatics Shared Facility, University of Alabama at Birmingham and UAB Comprehensive Cancer Center, Birmingham, AL 35294, USA

5.
Division of Hematology/Oncology, Department of Medicine, University of Alabama at Birmingham and UAB Comprehensive Cancer Center, 1802 6th Ave South, NP 2566, Birmingham, AL 35294-3300, USA

6.
Department of Radiation Oncology, The University of Alabama at Birmingham and UAB Comprehensive Cancer Center, Birmingham, AL 35294, USA

7.
IT'IS Foundation, Swiss Federal Institute of Technology, Zurich, Switzerland

8.
Rue de Verdun 20, Colmar 68000, France

Correspondence:
Dr FP Costa, E-mail: fredericoperegocosta@gmail.com;
Dr B Pasche, E-mail: Boris.Pasche@ccc.uab.edu

Abstract
Background:

Therapeutic options for patients with advanced hepatocellular carcinoma (HCC) are limited. There is emerging evidence that the growth of cancer cells may be altered by very low levels of electromagnetic fields modulated at specific frequencies.

Methods:

A single-group, open-label, phase I/II study was performed to assess the safety and effectiveness of the intrabuccal administration of very low levels of electromagnetic fields amplitude modulated at HCC-specific frequencies in 41 patients with advanced HCC and limited therapeutic options. Three-daily 60-min outpatient treatments were administered until disease progression or death. Imaging studies were performed every 8 weeks. The primary efficacy end point was progression-free survival greater than or equal to6 months. Secondary efficacy end points were progression-free survival and overall survival.

Results:
Treatment was well tolerated and there were no NCI grade 2, 3 or 4 toxicities. In all, 14 patients (34.1%) had stable disease for more than 6 months. Median progression-free survival was 4.4 months (95% CI 2.1–5.3) and median overall survival was 6.7 months (95% CI 3.0–10.2). There were three partial and one near complete responses.

Conclusion:
Treatment with intrabuccally administered amplitude-modulated electromagnetic fields is safe, well tolerated, and shows evidence of antitumour effects in patients with advanced HCC.


Voor het originele abstract zie:
www.nature.com/bjc/journal/vaop/ncurrent/abs/bjc2011292a.html .


Ga terug naar het hoofdmenu
Afdrukken | Vragen | RSS | Disclaimer